Pandemic and seasonal influenza: therapeutic challenges

Drug Discovery Today

Volumn 13, Issue 13-14, 2008, Pages 590-595

  Memoli, Matthew J ^a   Morens, David M ^a   Taubenberger, Jeffery K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; DAS 181; EXTENDED SPECTRUM BETA LACTAMASE; FIBROBLAST GROWTH FACTOR 4; FLUDASE; IMIPENEM; INACTIVATED VACCINE; INFLUENZA VACCINE; INOSINATE DEHYDROGENASE INHIBITOR; LIVE VACCINE; PENICILLIN G; RIBAVIRIN; RIMANTADINE; RNA DIRECTED RNA POLYMERASE; SIALIDASE INHIBITOR; SMALL INTERFERING RNA; STREPTOMYCIN; ZANAMIVIR;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIVIRAL RESISTANCE; AVIAN INFLUENZA; BACTERIAL PNEUMONIA; BRONCHOPNEUMONIA; CLOSTRIDIUM DIFFICILE; DRUG DOSAGE FORM COMPARISON; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITAL INFECTION; HOST SUSCEPTIBILITY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PANDEMIC; PROPHYLAXIS; PSEUDOMONAS; REVIEW; RNA INTERFERENCE; STREPTOCOCCUS PNEUMONIAE; SYMPTOMATOLOGY; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CROSS INFECTION; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; PHARMACOLOGY, CLINICAL; SEASONS;

EID: 45849113633     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.03.024     Document Type: Review

References (71)

1. Wright P.F., et al. Orthomyxoviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2005), Lippincott Williams & Wilkins 1691-1740
2. Thompson W.W., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
3. Cox N.J., and Subbarao K. Global epidemiology of influenza: past and present. Annu. Rev. Med. 51 (2000) 407-421
4. Taubenberger J.K., and Morens D.M. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 12 (2006) 15-22
5. Beveridge W. Influenza: The Last Great Plague an Unfinished Story (1977), Prodist
6. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 17 Suppl. 1 (1999) S3-S10
7. Morens D.M., and Fauci A.S. The 1918 influenza pandemic: insights for the 21st century. J. Infect. Dis. 195 (2007) 1018-1028
8. Johnson N.P., and Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76 (2002) 105-115
9. Taubenberger J.K., et al. The next influenza pandemic: can it be predicted?. JAMA 297 (2007) 2025-2027
10. Peiris J.S., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 (2004) 617-619
11. Webby R.J., and Webster R.G. Are we ready for pandemic influenza?. Science 302 (2003) 1519-1522
12. Webster R.G., and Govorkova E.A. H5N1 influenza-continuing evolution and spread. N. Engl. J. Med. 355 (2006) 2174-2177
13. Webster R.G., et al. H5N1 outbreaks and enzootic influenza. Emerg. Infect. Dis. 12 (2006) 3-8
14. WHO (2007) Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO (Vol. 2007), World Health Organization
15. Ungchusak K., et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352 (2005) 333-340
16. Yu H., et al. Human influenza A (H5N1) cases, urban areas of People's Republic of China, 2005-2006. Emerg. Infect. Dis. 13 (2007) 1061-1064
17. Yang Y., et al. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg. Infect. Dis. 13 (2007) 1348-1353
18. Abdel-Ghafar A.N., et al. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358 (2008) 261-273
19. Maines T.R., et al. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 12121-12126
20. Taubenberger J.K., and Morens D.M. The pathology of influenza virus infections. Annu. Rev. Pathol. 3 (2008) 499-522
21. Couch R.B. Prevention and treatment of influenza. N. Engl. J. Med. 343 (2000) 1778-1787
22. Subbarao K., and Luke C. H5N1 viruses and vaccines. PLoS Pathog. 3 (2007) e40
23. El Sahly H.M., and Keitel W.A. Pandemic H5N1 influenza vaccine development: an update. Expert Rev. Vaccines 7 (2008) 241-247
24. Haque A., et al. Confronting potential influenza A (H5N1) pandemic with better vaccines. Emerg. Infect. Dis. 13 (2007) 1512-1518
25. Mossad S.B. Influenza update 2007-2008: vaccine advances, pandemic preparation. Cleve Clin. J. Med. 74 (2007) 889-894
26. Tosh P.K., and Poland G.A. Emerging vaccines for influenza. Expert Opin. Emerg. Drugs 13 (2008) 21-40
27. Ferguson N.M., et al. Strategies for mitigating an influenza pandemic. Nature 442 (2006) 448-452
28. Hayden F.G., and Pavia A.T. Antiviral management of seasonal and pandemic influenza. J. Infect. Dis. 194 Suppl. 2 (2006) S119-S126
29. Hayden F.G. Antiviral resistance in influenza viruses-implications for management and pandemic response. N. Engl. J. Med. 354 (2006) 785-788
30. Neuzil K.M., et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 281 (1999) 901-907
31. Bright R.A., et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
32. Deyde V.M., et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196 (2007) 249-257
33. Belshe R.B., et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62 (1988) 1508-1512
34. Simonsen L., et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 24 (2007) 1811-1820
35. Treanor J.J., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283 (2000) 1016-1024
36. Kiso M., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
37. Dyer O. European agencies find 14% of flu isolates are resistant to oseltamivir. BMJ 336 (2008) 298
38. de Jong M.D., et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
39. Le Q.M., et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
40. Gilbert B.E., et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob. Agents Chemother. 27 (1985) 309-313
41. Torrence P.F. Combating the Threat of Pandemic Influenza Drug Discovery Approaches (2007), John Wiley & Sons, Inc.
42. Sun X.L. Recent anti-influenza strategies in multivalent sialyloligosaccharides and sialylmimetics approaches. Curr. Med. Chem. 14 (2007) 2304-2313
43. Jones J.C., et al. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 80 (2006) 11960-11967
44. Tsai C.H., et al. Antiviral therapy targeting viral polymerase. Curr. Pharm. Des. 12 (2006) 1339-1355
45. Li M.L., et al. The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits. EMBO J. 20 (2001) 2078-2086
46. Furuta Y., et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46 (2002) 977-981
47. Furuta Y., et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49 (2005) 981-986
48. Zhou H., et al. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral. Res. 76 (2007) 186-193
49. Tompkins S.M., et al. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8682-8686
50. Louria D.B., et al. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J. Clin. Invest. 38 1 Part 2 (1959) 213-265
51. Goodhart J. Influenza. In: Allbutt T., and Rolleston H. (Eds). System of Medicine vol. I (1905), MacMillan & Company 942-967
52. Lucke B. Pathology and bacteriology of pneumonia. Pennsylvania Med. J. 23 (1920) 369-371
53. MacCallum W. Pathological Studies in the recent epidemics of pneumonia. Tr. South Surg. Assoc. 31 (1919) 180-192
54. MacCallum W. Pathological anatomy of pneumonia associated with influenza. Johns Hopkins Hosp. Rep. 20 (1920) 149-249
55. Opie E., et al. The pathology and bacteriology of pneumonia following influenza. In: Opie E., et al. (Ed). Epidemic Respiratory Disease, The Pneumonias and Other Infections of the Respiratory Tract Accompanying Influenza and Measles (1921), C.V. Mosby 107-281
56. Lamb F., and Brannin E. The epidemic respiratory infection at Camp Cody, N. M. J. Am. Med. Assoc. 72 (1919) 1056-1062
57. Schwarzmann S.W., et al. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch. Intern. Med. 127 (1971) 1037-1041
58. As Antibiotic Discovery Stagnates A Public Health Crisis Brews. White Paper: Bad bugs, No Drugs (2004), Infectious Disease Society of America
59. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
60. Burden of Infections Among U. S. Nursing Home Residents. Campaign to prevent Antimicrobial Resistance in Healthcare Settings (2007), Centers for Disease Control
61. Francis J.S., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40 (2005) 100-107
62. Johnston B.L. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia - a critical review. Semin. Respir. Infect. 9 (1994) 199-206
63. Hageman J.C., et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg. Infect. Dis. 12 (2006) 894-899
64. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. Morb. Mortal. Wkly Rep. 56 (2007) 325-329
65. Spellberg B., et al. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38 (2004) 1279-1286
66. Executive summary. In WHO Global Strategy for Containment of Antimicrobial Resistance (2001), World Health Organization
67. Schunemann H.J., et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect. Dis. 7 (2007) 21-31
68. Fedson D.S. Statin protection against influenza and COPD mortality. Chest 132 (2007) 1406 [author reply 1406-1407]
69. Grijalva C.G., et al. Statins and influenza/COPD mortality. Chest 132 (2007) 1407 [author reply 1407-1408]
70. Vos E., and Mascitelli L. Statins have no role in pulmonary disease mortality. Chest 132 (2007) 1408 [author reply 1408-1409]
71. Rennie P., et al. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Respir. Res. 8 (2007) 38